Healthcare Services

Coagulation Factor Deficiency Market: Key Drivers and Evolution

April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Coagulation Factor Deficiency Market Between 2026 And 2030?

The coagulation factor deficiency market has demonstrated substantial growth in recent years. It is forecast to expand from $4.93 billion in 2025 to $5.3 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. This historical growth can be attributed to factors like enhanced diagnosis of bleeding disorders, increased accessibility to plasma-derived therapies, the expansion of hemophilia treatment centers, elevated patient awareness initiatives, and the development of specialty healthcare services.

The coagulation factor deficiency market size is projected to experience substantial growth over the next few years, expanding to $7.05 billion by 2030 with a compound annual growth rate (CAGR) of 7.4%. This projected growth can be attributed to several factors, including advancements in gene therapy development, a rising demand for personalized bleeding disorder treatments, the expansion of home care treatment models, an increasing focus on reducing treatment frequency, and growing investments in rare disease therapeutics. Key trends for the forecast period include the increasing adoption of recombinant coagulation factors, a rising use of gene therapy-based treatments, a growing preference for prophylactic treatment regimens, the expansion of home-based infusion therapies, and an enhanced focus on long-acting factor products.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/coagulation-factor-deficiency-global-market-report

Which Major Drivers Are Influencing The Expansion Of The Coagulation Factor Deficiency Market?

The anticipated rise in cases of blood-related disorders is projected to fuel the expansion of the coagulation factor deficiency market in the future. These disorders encompass various conditions impacting the creation, operation, or makeup of blood cells, platelets, or plasma, resulting in issues like anemia, coagulation difficulties, or immune system weaknesses. The increase in such disorders can be attributed to elements like an aging demographic, genetic tendencies, heightened public awareness, environmental influences, shifts in lifestyle, the increasing prevalence of chronic illnesses, and improvements in diagnostic tools enabling earlier identification. Coagulation factor deficiency treatments assist in handling blood-related disorders by supplying crucial clotting factors necessary to avert or manage profuse bleeding, particularly in conditions such as hemophilia, where the body’s intrinsic capacity to form blood clots is compromised. For example, as reported in September 2024 by the Leukemia and Lymphoma Society, a professional organization in the US, every 3 minutes, an individual in the US receives a diagnosis of leukemia, lymphoma, or myeloma. In 2024, approximately 187,740 individuals are projected to be diagnosed with these cancers, making up 9.4% of the anticipated 2,001,140 new cancer cases across the US. Furthermore, data from May 2024 from the National Health Service (NHS) England, a UK government-funded healthcare provider, indicates that approximately 17,000 people in England are currently living with sickle cell disease, an inherited blood disorder, with about 250 new cases diagnosed annually. Consequently, the rising occurrence of blood-related disorders is propelling the expansion of the coagulation factor deficiency market.

What Are The Different Segment Types In The Coagulation Factor Deficiency Market Segment Breakdown?

The coagulation factor deficiency market covered in this report is segmented –

1) By Product: Recombinant Coagulation Factor Concentrates, Plasma-Derived Coagulation Factor Concentrates, Biologics, Desmopressin, Other Product Types

2) By Deficiency Type: Haemophilia A, Hemophilia B, Von Willebrand Disease, Factor XI Deficiency, Factor XIII Deficiency, Other Treatment Types

3) By End Users: Hospitals, Clinics, Home Care, Other End Users

Subsegments:

1) By Recombinant Coagulation Factor Concentrates: Recombinant Factor VIII, Recombinant Factor IX, Recombinant Factor VIIa

2) By Plasma-Derived Coagulation Factor Concentrates: Plasma-Derived Factor VIII, Plasma-Derived Factor IX, Plasma-Derived Factor VII

3) By Biologics: Monoclonal Antibodies, Gene Therapy Products

4) By Desmopressin: Intravenous Desmopressin, Intranasal Desmopressin

5) By Other Product Types: Fresh Frozen Plasma (FFP), Prothrombin Complex Concentrates (PCC)

Which Trends Are Shaping The Coagulation Factor Deficiency Market?

Leading companies within the coagulation factor deficiency market are prioritizing the creation of advanced treatments, including single-dose gene therapy. Their aim is to offer sustained or possibly permanent remedies for individuals suffering from bleeding conditions such as hemophilia, thereby lessening the ongoing requirement for clotting factor infusions. A single-administration gene therapy is defined as a medical intervention that entails introducing or modifying genetic material inside a patient’s cells to manage or resolve an illness, with the goal of delivering enduring or permanent treatment outcomes following a sole application. An example occurred in April 2024, when Pfizer Inc., a pharmaceutical and biotechnology firm based in the US, disclosed that the U.S. Food and Drug Administration (FDA) had granted approval for BEQVEZ (fidanacogene elaparvovec-dzkt). This approval is for the management of adults with moderate to severe hemophilia B currently on factor IX (FIX) prophylaxis treatment. This particular therapy is a single-dose adeno-associated virus (AAV)-based gene therapy. Its purpose is to insert a working copy of the FIX gene, which codes for a highly active FIX variant, into the transduced cells. This one-time gene therapy allows individuals with hemophilia B to generate their own FIX, eliminating the need for regular FIX infusions.

Who Are The Well-Known Companies In The Coagulation Factor Deficiency Market?

Major companies operating in the coagulation factor deficiency market are Pfizer Inc., Bayer HealthCare Pharmaceuticals, Sanofi Genzyme, Novo Nordisk A/S, Baxter International Inc., CSL Behring LLC, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Swedish Orphan Biovitrum AB, Kedrion Biopharma Inc., Shanghai RAAS Blood Products Co. Ltd., LFB S.A., Biotest AG, BioMarin Pharmaceutical Inc., uniQure, Prothya Biosolutions, Bio Products Laboratory Ltd, Green Cross Corporation, Freeline Therapeutics, Aptevo Therapeutics, Hema Biologics LLC, Generation Bio Co, Intellia Therapeutics Inc.

Get The Full Coagulation Factor Deficiency Market Report:

https://www.thebusinessresearchcompany.com/report/coagulation-factor-deficiency-global-market-report

Which Region Leads The Coagulation Factor Deficiency Market In Overall Market Size?

North America was the largest region in the coagulation factor deficiency market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coagulation factor deficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Coagulation Factor Deficiency Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/coagulation-factor-deficiency-global-market-report

Browse Through More Reports Similar to the Global Coagulation Factor Deficiency Market 2026, By The Business Research Company

Hemostasis Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemostasis-products-global-market-report

Coagulation Analyzer Market Report 2026

https://www.thebusinessresearchcompany.com/report/coagulation-analyzer-global-market-report

Point Of Care Poc Coagulation Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/point-of-care-poc-coagulation-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795